Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001127602-19-035852
Filing Date
2019-12-26
Accepted
2019-12-26 17:13:22
Documents
1
Period of Report
2019-12-17

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form4a.html 4/A  
1 PRIMARY DOCUMENT form4a.xml 4/A 3802
  Complete submission text file 0001127602-19-035852.txt   5203
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703
Business Address
Sniecinski Megan (Reporting) CIK: 0001781480 (see all company filings)

Type: 4/A | Act: 34 | File No.: 000-23186 | Film No.: 191311082